NLRP3 (rs10754558) gene polymorphism and tumor necrosis factor alpha as predictors for disease activity and response to methotrexate and adalimumab in psoriasis.
Fatma Z KamelHeba Allah Mohamed HoseinyAya A El ShahawyGhada BoghdadiAlia A El ShahawyPublished in: BMC immunology (2024)
The NLRP3 (rs10754558) genotypes GC was associated with the severe form of psoriasis and with nonresponse to psoriasis medication. Therefore, NLRP3 (rs10754558) gene polymorphism is an important prognostic biomarker in psoriasis patients. The serum TNFα can be used as a predictor for response to therapy in psoriasis patients. More research for evaluation of role of the NLRP3 gene polymorphism in the genetic risks and treatment outcomes associated with psoriasis is still required.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- disease activity
- ejection fraction
- chronic kidney disease
- newly diagnosed
- atopic dermatitis
- peritoneal dialysis
- healthcare
- juvenile idiopathic arthritis
- nlrp inflammasome
- early onset
- patient reported outcomes
- mesenchymal stem cells
- climate change
- genome wide
- risk assessment
- drug induced